Dr. Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a “Foundation” grant from the Canadian Institutes of Health Research (CIHR). He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccine in the elderly.

Dr. Boivin is the author or co-author of 300 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of 9 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that will be operational in 2018, which will expand the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (MERS-CoV).

His research program focuses on the diagnosis, pathogenesis, and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu). More recently, he has also been interested in the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to develop rapid diagnostic tests, evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has developed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work will have a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections in certain groups of individuals.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
338 entries « 34 of 34 »

Boivin G, Handfield J, Murray G, Toma E, Lalonde R, Lazar JG, Bergeron MG

Quantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus-infected subjects with and without CMV disease by using PCR and the SHARP Signal Detection System.

Journal Article

J Clin Microbiol, 35 (2), pp. 525-6, 1997, ISSN: 0095-1137.

Abstract | Links:

Boivin G, Olson CA, Quirk MR, Kringstad B, Hertz MI, Jordan MC

Quantitation of cytomegalovirus DNA and characterization of viral gene expression in bronchoalveolar cells of infected patients with and without pneumonitis.

Journal Article

J Infect Dis, 173 (6), pp. 1304-12, 1996, ISSN: 0022-1899.

Abstract | Links:

Boivin G, Chou S, Quirk MR, Erice A, Jordan MC

Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease.

Journal Article

J Infect Dis, 173 (3), pp. 523-8, 1996, ISSN: 0022-1899.

Abstract | Links:

Boivin G, Olson CA, Quirk MR, St-Cyr SM, Jordan MC

Quantitation of human cytomegalovirus glycoprotein H gene in cells using competitive PCR and a rapid fluorescence-based detection system.

Journal Article

J Virol Methods, 51 (2-3), pp. 329-42, 1995, ISSN: 0166-0934.

Abstract | Links:

Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

Journal Article

J Infect Dis, 170 (1), pp. 68-75, 1994, ISSN: 0022-1899.

Abstract | Links:

Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH

Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis.

Journal Article

J Infect Dis, 168 (2), pp. 332-5, 1993, ISSN: 0022-1899.

Abstract | Links:

Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH

Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis.

Journal Article

Antimicrob Agents Chemother, 37 (2), pp. 357-9, 1993, ISSN: 0066-4804.

Abstract | Links:

Boivin G

[The emergence of viruses resistant to antiviral agents: a new challenge]

Journal Article

Union Med Can, 122 (1), pp. 31-6, 1993, ISSN: 0041-6959.

Abstract | Links:

338 entries « 34 of 34 »
Signaler des ajouts ou des modifications

Active projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, Subvention, Instituts de recherche en santé du Canada, Subventions Fondation, from 2016-07-01 to 2023-06-30
  • Canadian Immunization Research Network, Subvention, Instituts de recherche en santé du Canada, Réseau canadien de recherche sur l’immunisation, from 2014-06-01 to 2021-12-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2024-11-06
  • How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens, Subvention, Consortium québécois sur la découverte du médicament, from 2018-10-01 to 2022-09-30
  • Innovative therapeutic approaches for the 2019-novel coronavirus, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Possibilité de financement canadienne pour une intervention de recherche rapide contre la maladie à coronavirus 2019 (COVID-19), from 2020-02-01 to 2022-01-31
  • Sentinel surveillance, viral shedding, clinical characteristics and outcomes of confirmed and suspected hospitalized cases of COVID-19/SARS-CoV-2 infection in the Canadian Immunization Research Network (CIRN), Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Possibilité de financement pour une intervention de recherche rapide contre la COVID-19, from 2020-04-01 to 2021-03-31
  • Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Financement supplémentaire pour l’intégration du sexe comme variable biologique dans l’intervention de recherche rapide contre la COVID-19, from 2020-05-01 to 2021-03-31

Recently finished projects

  • Chaire de recherche du Canada sur les virus en émergence et la résistance aux antiviraux, Subvention, Secrétariat des Chaires de recherche du Canada, Chaires de recherche du Canada - Fonctionnement, from 2013-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery